| 22.3 -0.04 (-0.18%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.48 | 1-year : | 30.39 |
| Resists | First : | 24.38 | Second : | 26.02 |
| Pivot price | 23.47 |
|||
| Supports | First : | 21.75 | Second : | 18.09 |
| MAs | MA(5) : | 23.6 |
MA(20) : | 23.4 |
| MA(100) : | 18.27 |
MA(250) : | 17.96 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 17.5 |
D(3) : | 42.2 |
| RSI | RSI(14): 46.9 |
|||
| 52-week | High : | 49.95 | Low : | 6.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VOR ] has closed above bottom band by 19.0%. Bollinger Bands are 10.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 23.52 - 23.66 | 23.66 - 23.77 |
| Low: | 21.88 - 22.06 | 22.06 - 22.2 |
| Close: | 22.06 - 22.33 | 22.33 - 22.53 |
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Tue, 08 Sep 2026
VOR: Phase III MG trial enrollment complete; telitacicept poised for strong efficacy and market impact - TradingView
Tue, 08 Sep 2026
VOR: Phase III MG trial enrollment complete; robust efficacy and market expansion plans underway - TradingView
Tue, 08 Sep 2026
Vor Biopharma (VOR) Completes Enrollment in Phase 3 Trial as Mar - GuruFocus
Tue, 08 Sep 2026
A new trial for eye-related muscle weakness is planned for 2027. Vor Bio finished enrolling another. - Stock Titan
Tue, 08 Sep 2026
Vor Biopharma (VOR) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $VOR - MarketBeat
Tue, 01 Sep 2026
Vor Bio To Participate in Upcoming September Conferences - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 9.2 (%) |
| Held by Institutions | 85.9 (%) |
| Shares Short | 7,350 (K) |
| Shares Short P.Month | 7,290 (K) |
| EPS | 180.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -140 (M) |
| Levered Free Cash Flow | -80 (M) |
| PE Ratio | 0.12 |
| PEG Ratio | 0 |
| Price to Book value | -6.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|